evidence varies by claim

mKRAS-VAX

Cancer & Peptide Vaccines

mKRAS-VAX is indexed as peptide vaccine in the PeptideBase article library. It is referenced in “Can a KRAS Peptide Vaccine Prevent Pancreatic Cancer? What the First Human Trial Actually Shows” and 1 other PeptideBase article. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.

Research status: evidence varies by claim

Deep Dives on mKRAS-VAX

Start here for the plain-English articles connected to this peptide.

research_other12 min read

An Immune Response Is Not a Survival Benefit: What Personalized Pancreatic Cancer Vaccines Actually Show

Two small pancreatic cancer vaccine trials showed immune responses—not proven survival benefit. Understand the denominators, assay limits, safety, and registry gaps.

Read article

evidence-literacy10 min read

Can a KRAS Peptide Vaccine Prevent Pancreatic Cancer? What the First Human Trial Actually Shows

The first human mKRAS-VAX study generated mutant-KRAS-specific T-cell responses in 18 of 20 high-risk participants—but it did not prove pancreatic cancer prevention.

Read article

Quick Facts

Origin: Named peptide vaccine referenced in PeptideBase coverage
Category: Cancer & Peptide Vaccines

Research Areas